Evidence map›Paper›PMID 38842282›Full record

Observational studyJournal of the American Heart Association2024

Incidence and Risk Factors for New and Recurrent Infarcts in Adults With Sickle Cell Disease.

Lori C Jordan, Allison A King, Julie Kanter, Jeff Lebensburger, Andria L Ford, Taniya E Varughese, Lisa Garrett, Lauren Mullis, LeShana Saint Jean, Samantha Davis and 7 more

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Lori C JordanDivision of Pediatric Neurology, Department of Pediatrics Vanderbilt University Medical Center Nashville TN.ORCID 0000-0001-7240-0415
Allison A KingDivision of Hematology & Oncology, Department of Pediatrics Washington University School of Medicine St. Louis MO.ORCID 0000-0002-1951-6176
Julie KanterDivision of Hematology-Oncology, Department of Medicine University of Alabama at Birmingham Heersink School of Medicine Birmingham AL.ORCID 0000-0001-7002-8891
Jeff LebensburgerDivision of Hematology-Oncology, Department of Pediatrics University of Alabama at Birmingham, Heersink School of Medicine Birmingham AL.
Andria L FordDepartment of Neurology Washington University School of Medicine St. Louis MO.ORCID 0000-0003-0605-8943
Taniya E VarugheseDivision of Hematology & Oncology, Department of Pediatrics Washington University School of Medicine St. Louis MO.ORCID 0000-0002-7300-6986
Lisa GarrettDivision of Hematology, Department of Medicine Washington University School of Medicine St. Louis MO.
Lauren MullisDivision of Hematology-Oncology, Department of Pediatrics University of Alabama at Birmingham, Heersink School of Medicine Birmingham AL.
LeShana Saint JeanVanderbilt-Meharry Center of Excellence in Sickle Cell Disease Vanderbilt University Medical Center Nashville TN.ORCID 0000-0001-8982-8426
Samantha DavisDivision of Pediatric Neurology, Department of Pediatrics Vanderbilt University Medical Center Nashville TN.ORCID 0009-0004-5245-2647
Jeanine DumasDivision of Hematology-Oncology, Department of Pediatrics University of Alabama at Birmingham, Heersink School of Medicine Birmingham AL.
Adetola A KassimDivision of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center Nashville TN.ORCID 0000-0002-0484-5903
Mark RodeghierRodeghier Consulting Chicago IL.ORCID 0000-0001-7258-0073
Mustapha S HikimaDepartment of Radiology Muhammad Abdullahi Wase Teaching Hospital Kano Nigeria.
Mohammad A SuwaidDepartment of Radiology Aminu Kano Teaching Hospital Kano Nigeria.ORCID 0000-0003-2821-0213
Mohammed K SalehDepartment of Radiology Aminu Kano Teaching Hospital Kano Nigeria.
Michael R DeBaunVanderbilt-Meharry Center of Excellence in Sickle Cell Disease Vanderbilt University Medical Center Nashville TN.ORCID 0000-0002-0574-1604

Funding

Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lea K Davis · 2020 to 2026
$10.3M
MR-Derived Cerebral Oxygen Metabolism underlying Ischemic Vulnerability in Sickle Cell DiseaseR01HL129241 · NHLBI · WASHINGTON UNIVERSITY · PI Hongyu An, Robert A Campbell · 2015 to 2026
$6.6M
Mid-America Regional Coordinating Center (MARCC)U24NS107230 · NINDS · WASHINGTON UNIVERSITY · PI Andria Lee Ford, Peter David Panagos · 2018 to 2026
$2.8M
Mentoring in Patient-Oriented Research focused on Neurological Complications of Sickle Cell DiseaseK24HL147017 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JORDAN, LORI CHAFFIN · 2019 to 2023
$547k
NHLBI NIH HHS K24 HL147017NHLBI NIH HHS R01 HL129241NICHD NIH HHS P50 HD103537NINDS NIH HHS U24 NS107230
6 · The paper itself

Abstract

backgroundMost adults with sickle cell disease will experience a silent cerebral infarction (SCI) or overt stroke. Identifying patient subgroups with increased stroke incidence is important for future clinical trials focused on stroke prevention. Our 3-center prospective cohort study tested the primary hypothesis that adults with sickle cell disease and SCIs have a greater incidence of new stroke or SCI compared with those without SCI. A secondary aim focused on identifying additional risk factors for progressive infarcts, particularly traditional risk factors for stroke in adults. METHODS AND

resultsThis observational study included adults with sickle cell disease and no history of stroke. Magnetic resonance imaging scans of the brain completed at baseline and >1 year later were reviewed by 3 radiologists for baseline SCIs and new or progressive infarcts on follow-up magnetic resonance imaging. Stroke risk factors were abstracted from the medical chart. Time-to-event analysis was utilized for progressive infarcts. Median age was 24.1 years; 45.3% of 95 participants had SCIs on baseline magnetic resonance imaging. Progressive infarcts were present in 17 participants (17.9%), and the median follow-up was 2.1 years. Incidence of new infarcts was 11.95 per 100 patient-years (6.17-20.88) versus 3.74 per 100 patient-years (1.21-8.73) in those with versus without prior SCI. Multivariable Cox regression showed that baseline SCI predicts progressive infarcts (hazard ratio, 3.46 [95% CI, 1.05-11.39];

conclusionsSelecting individuals with SCIs and hypertension for stroke prevention trials in sickle cell disease may enrich the study population with those at highest risk for infarct recurrence.

Indexed as

Anemia, Sickle CellCerebral InfarctionMagnetic Resonance ImagingRecurrenceAdolescentAdultDisease ProgressionFemaleHumansHypertensionIncidenceMaleProspective StudiesRisk AssessmentRisk FactorsStrokehypertensionsickle cell diseasesilent infarctstroke

Identifiers

PMID38842282
PMCPMC11255756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.